Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

TUNG-HUNG SUJIA-HORNG KAO2021-03-092021-03-0920171478-3223https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009070606&doi=10.1111%2fliv.13315&partnerID=40&md5=57970671fae962f592d49280a495f9bchttps://scholars.lib.ntu.edu.tw/handle/123456789/551095[SDGs]SDG3entecavir; antivirus agent; entecavir; guanine; virus DNA; acute hepatitis A; antiviral therapy; cancer risk; Child Pugh score; chronic hepatitis B; decompensated liver cirrhosis; drug response; hepatitis E; human; incidence; Letter; liver cell carcinoma; liver cirrhosis; mortality; public health service; risk reduction; superinfection; survival; Taiwan; analogs and derivatives; chronic hepatitis B; genetics; Hepatitis B virus; liver cell carcinoma; liver cirrhosis; liver tumor; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver NeoplasmsResponse to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patientsletter10.1111/liv.13315280709822-s2.0-85009070606